Laboratory Products
Thermo Fisher Scientific Announces New Strategic Partnership with Megaware
Apr 18 2008
The two companies will market a new comprehensive end-to-end software solution which provides bioequivalence functionality on a single platform to help speed up and manage clinical trials. Rapid market
growth in generic drug production is driving the requirement for fast efficient bioequivalence studies to meet FDA ANDA guidelines (Abbreviated New Drug Applications). A unified software solution will
aggregate disparate software systems for organisations that demand tools to speed service and management of this critical and regulated IPO.
Thermo Fisher and Megaware will jointly sell, market and support the new solution in the field. Thermo Fisher will bring its bioanalytical expertise to the partnership and Megaware, with headquarters in
Westborough, MA and Mumbai, India, will deliver the end-to-end technological focus combined with on-the-ground market knowledge. The new solution will offer higher throughput, greater levels of compliance
and standardisation of bioequivalence processes.
Digital Edition
Lab Asia 31.2 April 2024
April 2024
In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...
View all digital editions
Events
Apr 22 2024 Marrakech, Morroco
Making Pharmaceuticals Exhibition & Conference
Apr 23 2024 Coventry, UK
Apr 23 2024 Kintex, South Korea
Apr 23 2024 Seoul, South Korea
Apr 24 2024 Jakarta, Indonesia